New Medication for Uncontrolled Eczema

Trial Objective

New Medication for Uncontrolled EczemaOur researchers are studying a new medication called dupilumab to determine how it affects the immune system, water loss in the skin, and the amount of bacteria in the skin of adults with atopic dermatitis (eczema).

People with chronic atopic dermatitis have dry, scaly, itchy skin and often have repeat viral and bacterial skin infections. A bacteria known as Staph aureus, or Staph, causes many of these infections. To control their symptoms, many people with atopic dermatitis use long-term topical or oral treatments. Long-term use of these medications can have side effects. For this reason, new treatments are being researched, especially for patients whose symptoms are not controlled by existing medications. The Food and Drug Administration recently approved dupilumab for moderate-to-severe atopic dermatitis.

Enrollment

This trial is active and currently recruiting.

Who Can Participate

Adults who have had chronic atopic dermatitis for at least three years, have it on more than 10 percent of their body, and have at least three active lesions that measure at least 4-by-4 centimeters on  their arms or legs may be eligible to participate. 

Age: 18-75    Gender: Any Gender


Estimated Time Commitment

10 visits and 1 telephone call over about 6-7 months



Compensation

Provided

Trial Contact

For more information, contact:

Caroline Bronchick

Caroline Bronchick
303.398.1409

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)


Request More Information

*
*
*
*